Pharma is built to overcome, but focus on fundamentals remains key.
Arda Ural, PhD
Advertisement
Arda Ural, Ph.D., is the Americas Industry Markets Leader for Health Sciences and Wellness at Ernst & Young LLP (EY). Arda oversees the life sciences team that covers industry mergers and acquisitions.
Articles by Arda Ural, PhD
A recent analysis of the biotech market shows promising signs.
The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.
Considerations for biopharma to transform itself beyond the COVID-19 crisis, by Arda Ural.
Advertisement
Latest Updated Articles
Biopharma Q1 Earnings: The Impact of COVID-19Published: May 21st 2021 | Updated:
- Navigating the Recession and Patent Expirations
Published: July 6th 2023 | Updated:
Leading Through a Historical SingularityPublished: May 28th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
4
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
5
